Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cells

Rheumatology

Volumn 47, Issue 4, 2008, Pages 451-453

  Baslund, B ^a   Gregers, J ^b   Nielsen, C H ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Genetic polymorphism; Methotrexate; Reduced folate carrier

Indexed keywords

METHOTREXATE; REDUCED FOLATE CARRIER; TETANUS TOXOID; ANTIRHEUMATIC AGENT; CARRIER PROTEIN; FUNGUS ANTIGEN;

ARTICLE; B LYMPHOCYTE; CANDIDA ALBICANS; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG UPTAKE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETICS; PRIORITY JOURNAL; BLOOD; CELL CULTURE; GENETICS; HELPER CELL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ANTIGENS, FUNGAL; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; CANDIDA ALBICANS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; GENOTYPE; HUMANS; LYMPHOCYTE ACTIVATION; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; POLYMORPHISM, GENETIC; T-LYMPHOCYTES, HELPER-INDUCER; TETANUS TOXOID;

EID: 43049166008     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken073     Document Type: Article

References (15)

1. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992;35:138-45.
2. Alarcon GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989;32:671-6.
3. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194-210.
4. Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999;17:313-20.
5. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004;50:1370-82.
6. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006;54:1366-77.
7. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832-4.
8. Dervieux T, Kremer J, Lein DO et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004;14:733-9.
9. Nielsen CH, Albertsen L, Bendtzen K, Baslund B. Methotrexate induces poly(ADPribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4T cells. Clin Exp Immunol 2007;148:288-95.
10. Christensen J, Leslie RG. Quantitative measurement of Fc receptor activity on human peripheral blood monocytes and the monocyte-like cell line, U937, by laser flow cytometry. J Immunol Methods 1990;132:211-9.
11. Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M. Reduced folate carrier-1 80G > A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J 2007;7:404-7.
12. Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-95.
13. Whetstine JR, Gifford AJ, Witt T et al. Single nucleotide polymorphisms in the human reduced folate carrier: Characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 2001;7:3416-22.
14. Wolf J, Stranzl T, Filipits M et al. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:564-8.
15. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: Translation of basic biology to cancer etiology and therapy. Cancer Metast Rev 2007;26:111-28.